Clinical effectiveness and costs of the Sugarbaker procedure for the treatment of pseudomyxoma peritonei

Health Technology Assessment

Volumn 8, Issue 7, 2004, Pages

  Bryant, J ^a   Clegg, A J ^a   Sidhu, M K ^a   Brodin, H ^a   Royle, P ^a   Davidson, P ^a  

^a Wessex Institute for Health Research and Development   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; MELPHALAN; MITOMYCIN C; SEMUSTINE; STREPTOZOCIN; VINCRISTINE;

ANASTOMOSIS LEAKAGE; CASE STUDY; CHEMOSURGERY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DATA BASE; FISTULA; HEALTH CARE COST; HOSPITAL PERSONNEL; HUMAN; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MONTE CARLO METHOD; PANCREATITIS; PERITONEUM PSEUDOMYXOMA; PUBLICATION; QUALITY CONTROL; REVIEW; SENSITIVITY ANALYSIS; SMALL INTESTINE OBSTRUCTION; SMALL INTESTINE PERFORATION; UNITED KINGDOM; UNITED STATES; WOUND INFECTION;

EID: 1442351123     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta8070     Document Type: Review

References (13)

1. Sugarbaker PH, Ronnett BM, Archer A, Averbach AM, Bland R, Chang D, et al. Pseudomyxoma peritonei syndrome. Adv Surg 1996;30:233-80.
2. Hinson FL, Ambrose NS. Pseudomyxoma peritonei. Br J Surg 1998;85:1332-9.
3. Wirtzfeld DA, Rodriguez-Bigas M, Weber T, Petrelli NJ. Disseminated peritoneal adenomucinosis: a critical review. Ann Surg Oncol 1999;6:797-801.
4. Sugarbaker PH. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg 1994;219:109-11.
5. Sherer DM, Abulafia O, Eliakim R. Pseudomyxoma peritonei: a review of current literature. Gynecol Obstet Invest 2001;51:73-80.
6. Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001;92:85-91.
7. Esquivel J, Sugarbaker PH. Clinical presentation of the pseudomyxoma peritonei syndrome. Br J Surg 2000;87:1414-18.
8. International Classification of Diseases: Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death, based on the recommendations of the Ninth Revision Conference, 1975, and adopted by the Twenty-Ninth World Health Assembly. World Health Organization. 1977; Vol. 1, p. 124.
9. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD guidelines for those carrying out or commissioning reviews. CRD Report 4. (2nd ed. York: NHS Centre for Reviews and Dissemination; 2001.
10. Sugarbaker PH. Cytoreductive surgery and perioperative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001;27:239-43.
11. Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001;88:458-63.
12. Smith JW, Kemeny N, Caldwell C, Banner P, Sigurdson E, Huvos A. Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1992; 70:396-401.
13. Sugarbaker PH, Zhu BW, Sese GB, Shmookler B. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 1993;36:323-9.